			Home About us Contact

Poster Presentations (poster + presentation)

Distribution by Scientific Domains

Medical Sciences	64%
Physics and Astronomy	11%

Selected Abstracts

XXVII International Congress of the International Academy of Pathology October 12-17, 2008, Athens, Greece POSTER PRESENTATIONS

HISTOPATHOLOGY, Issue 2008
Article first published online: 24 SEP 200
First page of article [source]

MODERATED (ORAL) POSTER PRESENTATIONS

THE JOURNAL OF SEXUAL MEDICINE, Issue 2010
Article first published online: 2 SEP 2010
First page of article [source]

ASGBI Abstracts 2008: Poster Presentations

BRITISH JOURNAL OF SURGERY (NOW INCLUDES EUROPEAN JOURNAL OF SURGERY), Issue S3 2008
You have free access to this content
The Annual Scientific Meeting of the Association of Surgeons of Great Britain and Ireland takes place this year at Bournemouth International Centre, Bournemouth, UK (14th , 16th May 2008), under the presidency of Professor Brian J Rowlands. To view all abstracts of poster presentations from this meeting, please click the pdf link on this page. Copyright © 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. [source]

Oral and Poster Presentations

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Issue S2 2010
Article first published online: 28 APR 2010
First page of article [source]

Poster presentations: Topic A

JOURNAL OF PEPTIDE SCIENCE, Issue S1 2002
Article first published online: 24 JUN 200
[source]

Poster presentations: Topic A

JOURNAL OF PEPTIDE SCIENCE, Issue S1 2002
Article first published online: 24 JUN 200
[source]

Poster presentations: Topic A

JOURNAL OF PEPTIDE SCIENCE, Issue S1 2002
Article first published online: 24 JUN 200
[source]

ASGBI Abstracts 2009: Poster presentations

BRITISH JOURNAL OF SURGERY (NOW INCLUDES EUROPEAN JOURNAL OF SURGERY), Issue S4 2009
ASGBI abstracts 2009 Poster presentations
The Annual Scientific Meeting of the Association of Surgeons of Great Britain and Ireland takes place this year at the Scottish Exhibition and Conference Centre, Glasgow, UK (13th,15th May 2009), under the presidency of Professor Michael Horrocks. To view the abstracts from this meeting, please click the pdf link on this page. Copyright © 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. [source]

ASGBI abstracts 2007 Poster presentations

BRITISH JOURNAL OF SURGERY (NOW INCLUDES EUROPEAN JOURNAL OF SURGERY), Issue S2 2007
Article first published online: 13 APR 200
The Annual Scientific Meeting of the Association of Surgeons of Great Britain and Ireland takes place this year at Manchester Central (18th - 20th April 2007), under the presidency of Professor Brian J Rowlands. To view all abstracts of poster presentations from this meeting, please click the pdf link on this page. [source]

Preface: phys. stat. sol. (c) 1/12

PHYSICA STATUS SOLIDI (C) - CURRENT TOPICS IN SOLID STATE PHYSICS, Issue 12 2004
Chair person Mohammad Ghafari
The Second Seeheim Conference on Magnetism (SCM2004) was the second conference in the tri-annual series of this conference series on magnetism, organized under the auspices of Darmstadt University of Technology, Forschungszentrum Karlsruhe and Ulm University. SCM2004 was held from 27 June to 1 July 2004. The location was the Lufthansa Training Center in Seeheim located conveniently in central Germany and easily accessible by air, train and car. The purpose of the meeting was to provide an opportunity to present and discuss recent developments in the field of magnetic nanomaterials. SCM2004 was focused on the latest developments in specific areas of magnetism (nanostructured materials, surfaces, interfaces and nanoparticles) and covered fundamental aspects of magnetism as well as applications. The most recent results were presented in the form of invited and contributed talks as well as posters. The topical areas were: ,,hard and soft magnetic materials ,,magnetic interactions ,,magnetization processes ,,spin dependent transport properties ,,nanostructured materials ,,applications. The first conference of this series was held in Seeheim in 2001. The papers from the 2001 conference were published in a regular issue of physica status solidi (a) 189, Nos. 2, 3 (2002), and since their publication they have been downloaded from the Web more than 14,000 times. This cleary demonstrates both the interest in and the need for this conference series. Our second meeting was attended by participants from 36 countries. A total number of 271 papers correlating nanostructure and magnetic properties were selected for presentation. Throughout the meeting a total of 51 talks was given; the remaining 220 papers were selected for poster presentation. The conference proceeded in an informal and very friendly atmosphere among the researchers from various parts of the world. We are grateful to the Deutsche Forschungsgemeinschaft, Forschungszentrum Karlsruhe and Darmstadt University of Technology for their kind financial support. We are looking forward to welcoming again participants of SCM2004 at the Third Seeheim Conference on Magnetism, planned for 2007 in Seeheim. [source]

Review of bupropion for smoking cessation

DRUG AND ALCOHOL REVIEW, Issue 2 2003
ROBYN RICHMOND
Abstract The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major change in the options available for smoking cessation pharmacotherapy. Bupropion is a selective re-uptake inhibitor of dopamine and noradrenalin which prevents or reduces cravings and other features of nicotine withdrawal. Bupropion is a useful oral and non-nicotine form of pharmacotherapy for smoking cessation. For this review a total of 221 papers were reviewed plus poster presentations. This review examines in detail original clinical trials on efficacy, categorised according to whether they were acute treatment trials in healthy smokers; studies in specific populations such as people with depression, chronic obstructive pulmonary disease (COPD) or cardiovascular disease; or relapse prevention studies. Overall, these studies in varying populations comprising over four thousand subjects, showed bupropion consistently produces a positive effect on smoking cessation outcomes. The evidence highlights the major public health role that bupropion has in smoking cessation. The methodological issues of published clinical trials reporting one year outcomes were examined in detail including: completeness of follow-up; loss to follow-up; intention to treat analysis; blindness of assessment; and validation of smoking status. The review discusses contraindications, adverse effects, dose and overdose, addictive potential, and the role of bupropion in reducing cessation-related weight gain. Bupropion combined with or compared to other pharmacotherapies (nicotine patch; nortriptyline) is considered. Impressive evidence exists for the use of bupropion in smoking cessation among difficult patients who are hard-core smokers such as those with cardiovascular disease, chronic obstructive pulmonary disease (COPD) and depression. Bupropion reduces withdrawal symptoms as well as weight gain and is effective for smoking cessation for people with and without a history of depression or alcoholism. Serious side effects of bupropion use are rare. The major safety issue with bupropion is risk of seizures (estimated at approximately 0.1%) and it should not be prescribed to patients with a current seizure disorder or any history of seizures. In clinical trials of bupropion for smoking cessation no seizures were reported. Allergic reactions occur at a rate of approximately 3% and minor adverse effects are common including dry mouth and insomnia. [source]

Program: Twenty Fourth Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders

MOVEMENT DISORDERS, Issue 6 2010
Article first published online: 26 APR 2010
The symposium will consist of current issues in genetic and environmental contributions to Parkinson's disease and other movement disorders with peer-reviewed platform and poster presentations designed to communicate recent research advances, including new pharmacological and non-pharmacological treatment options, in the field of Parkinson's disease, Huntington's disease, ataxia, dystonia, myoclonus, Tourette's syndrome, tremor and other movement disorders thereby enhancing patient care. [source]

Program: Twenty Third Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders

MOVEMENT DISORDERS, Issue 12 2009
Article first published online: 11 SEP 200
The symposium will consist of two keynote speakers and peer-reviewed platform and poster presentations designed to communicate recent research advances, including new pharmacological and non-pharmacological treatment options, in the field of Parkinson's disease, Huntington disease, ataxia, dystonia, myoclonus, Tourette's syndrome, Essential Tremor and other movement disorders thereby enhancing patient care. Professionals in neurology and related disciplines as well as practitioners, psychologists, educators, and researchers are invited to attend. The gaps in clinical practice we wish to address are the unmet needs pertaining to the translational and clinical evaluation, along with the care and treatment of patients and families affected by Parkinson's disease and other movement disorders. At the conclusion of this session, participants should be able to: 1) Identify and describe by scholarly review, oral presentation and group discussion the current research into the diagnosis, prevention and treatment of Parkinson's disease (PD) and Essential Tremor (ET) which may be relevant to current treatment or which may lead to the development of further research protocols; 2) Distinguish and assess the important advances in research and clinical treatments relating to Parkinson's disease and Essential Tremor in terms of available treatment options or new methodologies for clinical research; 3) Explain new pharmacological and non-pharmacological treatment options available for Parkinson's disease and other movement disorders in connection with their clinical practice or with regard to further clinical research methods; 4) Interpret the mechanisms (genetic, environmental, pathophysiology, neurobiology) linked to Parkinson's disease and other movement disorders when assessing Parkinson's disease or other movement disorder patients or when developing new research protocols; and 5) Employ diagnostic approaches and tools available for assessing Parkinson's disease and Essential Tremor when diagnosing new patients or when conducting clinical research. [source]

Preface: phys. stat. sol. (a) 205/8

PHYSICA STATUS SOLIDI (A) APPLICATIONS AND MATERIALS SCIENCE, Issue 8 2008
Guest Editor Elvira Fortunato
Advances in Transparent Electronics: From Materials to Devices II This issue of physica status solidi contains selected papers presented in Symposium I "Advances in Transparent Electronics: From Materials to Devices II" at the European Materials Research Society Spring Meeting held in Strasbourg, France, from 28 May to 1 June 2007. This was the second meeting in Europe covering this topic. It was attended by scientists from 33 different countries, with special emphasis to the Republic of South Korea and Japan (20% and 10%, respectively, of the total of papers presented). The symposium programme consisted of 9 invited talks, 45 oral presentations and 122 poster presentations, in total 176 contributions, from which 60 were selected for publication in the proceedings, representing nearly 35% of the submitted communications. Topics ranging from the fundamental understanding of physical phenomena to materials and devices have been covered, with special emphasis on the following ones: ,,Materials and processing for transparent electronics ,,Characterization and modelling ,,New devices (nano, micro and macro) ,,New applications The success of this symposium was the result of the contributions of many dedicated people. It is a pleasure for me to thank the symposium organizers (H. Hosono, Japan, J. Wager, USA, G. Kiriakidis, Greece, and S. Y. Lee, Korea) for their availability and help during the preparation and follow up of this symposium as well as all the individual referees, who donated their time to help making this a successful and scientific strong contribution for the international community on transparent electronics. I also would like to thank the two voluntary symposium assistants (P. Barquinha and G. Gonçalo) who helped before, during and after the symposium. Since the work is not limited to what was done before and during the conference, I also have to emphasize a detailed, delicate and long work that has been done after the conference was over, in close cooperation with Prof. Martin Stutzmann and Dr. Stefan Hildebrandt, for the edition of this special issue. I also would like to thank the E-MRS staff (C. Kocher and S. Schoeffter) for the unlimited time, energy and professionalism given for the success of this symposium. Without their assistance the symposium would not have been the success that it was. I also gratefully acknowledge the financial support of our main sponsors who made the symposium possible: ,,FCT-UNL, Portugal ,,Hewlett-Packard, Ireland ,,Horiba Jobin Yvon, France ,,Canon, Japan [source]

Latest news and product developments

PRESCRIBER, Issue 19 2008
Article first published online: 16 OCT 200
ARBs less effective than ACE inhibitors? The efficacy of angiotensin-II receptor blockers (ARBs) in preventing cardiovascular events in high-risk patients has been challenged by the findings of a large randomised trial (Lancet 2008 published online; doi 10.1016/ S0140-6736(08)61242-8). In the TRANSCEND trial, 5926 patients with cardiovascular disease or diabetes with end-organ damage who could not tolerate ACE inhibitor therapy were randomised to placebo or telmisartan (Micardis) 80mg per day in addition to standard therapies. After 56 months, mean blood pressure was lower with telmisartan (by 4.0/2.2mmHg) but there were no significant differences between telmisartan and placebo in the risk of cardiovascular events , a composite of cardiovascular death, myocardial infarction, stroke, or hospitalisation for heart failure. Hospitalisation for cardiovascular reasons were slightly but significantly reduced by telmisartan (33 vs 30 per cent). MHRA: fentanyl patch errors potentially fatal Errors in dosing, accidental exposure and enhanced absorption from heat exposure have resulted in life-threatening and fatal incidents with transdermal fentanyl, warns the MHRA in its latest Drug Safety Update (September 2008). There is also evidence that fentanyl patches are being prescribed for nonlicensed indications, including treatment of opioid-naive patients. Other topics in this issue include managing adverse reactions to HPV vaccine and an update on new cases of progressive multifocal leucoencephalopathy associated with natalizumab (Tysabri). Call for DURG research The Drug Utilisation Research Group is inviting abstracts for oral and poster presentations at its 20th annual meeting on 5 February 2009. The theme of the morning session is ,Whose prescribing budget is it anyway?'. Abstracts will be accepted on any drug utilisation research studies and will be published in the Journal of Pharmacoepidemiology and Drug Safety. Information is available at www.durg.org.uk the deadline for submissions is 1 December. Early bromocriptine no benefit in Parkinson's Initiating treatment of Parkinson's disease with the dopamine agonist bromocriptine offers no long-term benefit compared with levodopa, the UK Parkinson's Disease Research Group trial has shown (Neurology 2008;71:474-80). After 14 years' follow-up of 166 patients, there were no differences in the prevalence of motor complications, dementia or mortality, but levodopa was associated with superior scores of disability and physical functioning. The authors say the belief that early dopamine agonist treatment is neuroprotective in Parkinson's disease should be abandoned. Ezetimibe with statin cancer risk ,not credible' Analysis of data pooled from two large trials provides ,no credible evidence' that ezetimibe (Ezetrol) is associated with an increased risk of cancer when added to statin therapy (N Engl J Med 2008 published online; doi 10.1056/NEJMsa0806603). A possible link with increased risk of cancer with ezetimibe plus simvastatin was suggested by the SEAS trial (N Engl J Med 2008 published online; doi 10.1056/NEJMoa 0804602). This hypothesis was tested in two trials involving more than 20 500 patients over 1.0-2.7 years. There was no excess of cancer overall or at particular sites; cancer deaths were more numerically but not significantly higher with ezetimibe and there was no evidence of increased risk with duration of treatment. Telmisartan provides no advantage after stroke Adding telmisartan (Micardis) to standard treatment after ischaemic stroke does not reduce morbidity, US investigators report (N Engl J Med 2008 published online; doi 10.1056/NEJMoa 0804593). A total of 20 332 patients with recent ischaemic stroke were randomised to placebo or telmisartan 80mg per day in addition to antiplatelet therapy and antihypertensive agents. After 2.5 years, blood pressure was 3.8/2.0mmHg lower in patients taking telmisartan but there were no significant differences from placebo in the risks of recurrent stroke, cardiovascular events or new-onset diabetes. Copyright © 2008 Wiley Interface Ltd [source]